Skip to Content

'
Nathan H Fowler, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

My interest in immunomodulatory agents began during my hematology/oncology fellowship at Georgetown University Hospital, where I helped develop some of the first protocols to use lenalidomide in CLL.  Since joining the faculty at MD Anderson Cancer Center, the goal of my clinical research has been to further develop novel therapeutic regimens utilizing immunomodulatory agents to benefit patients with low grade non-Hodgkins lymphoma.  I serve as the chairman of several phase I and investigator-initiated phase II trials for patients with non-Hodgkins lymphoma which includes leading the largest clinical study to use immunomodulatory drugs for untreated low grade lymphoma.  I have had the opportunity to develop collaborative relationships with basic scientists across multiple departments, and as a member of the phase I team I have experience developing cutting edge translational projects for patients with lymphoma.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: Unit 429
Houston, TX 77030
Room Number: FC6.3064
Phone: 713-792-2860
Fax: 713-794-5656

Education & Training

Degree-Granting Education

2001 University of Texas Medical Branch, Galveston, TX, MD, Medicine
1997 University of Houston, Houston, TX, BS, Biology

Postgraduate Training

7/2006-6/2007 Chief Fellow, Georgetown University, Washington, DC
7/2004-8/2007 Clinical Fellowship, Hematology/Oncology, Georgetown University, Washington, DC
7/2002-6/2004 Clinical Residency, University of Texas Medical Branch, Galveston, TX
7/2001-6/2002 Clinical Internship, University of Texas Medical Branch, Galveston, TX

Board Certifications

8/2008 Medical Oncology
8/2004 American Board of Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2007-5/2013

Administrative Appointments/Responsibilities

Co-Director, Clinical and Translational Research Program, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 11/2012-present
Team Lead, Low Grade Lymphoma Research Group, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2010-present
Team Lead, CNS Lymphoma Research Group, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2009-present

Military or Other Governmental Service

Nuclear, Biological and Chemical Defense Specialist, US Army, 1988-1991

Institutional Committee Activities

Member, Clinical Research Committee, 9/2009-present

Honors and Awards

2006-2007 Georgetown Chief Fellow
1996 Natural Science and Mathematics Scholar and Fellow
1995-1996 Order of Omega Greek Honor Society
1994-1996 Dean's List
1991 National Defense Medal, US Army
1991 Overseas Service Ribbon, US Army
1990 Army Achievement Medal, US Army
1990 Valedictorian. Nuclear, Biological, and Chemical Defense School, US Army

Selected Publications

Peer-Reviewed Original Research Articles

1. Nasser QJ, Pfeiffer ML, Romaguera J, Fowler N, Debnam JM, Samaniego F, El-Sawy T, McLaughlin P, Bakhoum MF, Esmaeli B. Clinical Value of Magnetic Resonance Imaging and Other Baseline Testing for Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma. Leuk Lymphoma. e-Pub 8/2013. PMID: 23879202.
2. Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 162(1):138-41, 7/2013. e-Pub 4/2013. PMID: 23590726.
3. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, Baladandayuthapani V, Luong A, Vega F, Fowler N, Dong C, Davis RE, Neelapu SS. Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment. J Immunol 190(12):6681-93, 6/15/2013. e-Pub 5/17/2013. PMCID: PMC3680117.
4. Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell Non-Hodgkin lymphoma. Br J Haematol. e-Pub 6/2013. PMID: 23795711.
5. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera JE, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah JJ, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia, 4/2013. e-Pub 4/2013. PMID: 23545991.
6. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 4/2013. e-Pub 12/29/2012. PMID: 23276888.
7. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. J Clin Oncol 31(1):88-94, 1/2013. e-Pub 10/2012. PMID: 23045577.
8. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716-23, 7/2012. e-Pub 6/6/2012. PMID: 22677155.
9. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(26):6373-8, 6/28/2012. e-Pub 5/14/2012. PMID: 22586182.
10. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 6/2012. e-Pub 10/19/2011. PMID: 22015451.
11. Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B, Williams ME, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, Cheson BD. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The phase II VERTICAL study. J Clin Oncol 29(25):3389-95, 9/2011. e-Pub 8/2011. PMID: 21810687.
12. Fowler N. Role of Maintenance Rituximab (Rituxan) Therapy in the Treatment of Follicular Lymphoma. Pharmacy and Therapeutics 36(9):590-598, 9/2011.
13. Shahani S, Ahmad A, Barakat FH, Chuang HH, Fowler NH, Myers JN, Stava C, Habra MA. F-18 FDG PET/CT detecting thyroid plasmacytoma after the successful treatment of gastric large B-cell lymphoma. Clin Nucl Med 36(4):317-9, 4/2011. PMID: 21368613.
14. Mazloom A, Rodriguez A, Ha CS, Medeiros LJ, Wogan C, Shihadeh F, Allen P, Fowler N, Dabaja B. Incidence of gastric involvement in patients with nongastrointestinal extranodal marginal zone lymphoma. Cancer. e-Pub 12/2010. PMID: 21157949.
15. Phan J, Mazloom A, Medeiros J, Shihadeh F, Rodriguez A, Fayad L, Fowler N, Reed V, Horace P and Dabaja B. The benefit of consolidative radiation therapy in patients with diffuse large b-cell lymphoma treated with R-CHOP chemotherapy. Journal of Clinical Oncology 28(27)(4):4105-7, 9/2010. PMID: 20713859.
16. Mazloom A, Fowler N, McLaughlin P, Iyengar P, Cabinillas F, Fayad L, Pro B, Medeiros J, Rodriguez A, Reed V, Urbauer D, Gonzalez G, Dabaja B. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma 51(7):1217-1224, 7/2010. PMID: 20443676.
17. Goldman L, Ezzat S, Mokhtar N, Abdel-Hamid A, Fowler N, Gouda I, Eissa S, Abdel-Hamid M, Loffredo C. Viral and non-viral risk factors for non-Hodgkin's Lymphoma in Egypt: heterogeneity by histological and immunological subtypes. Cancer Causes Control 20(6):981-7, 8/2009. e-Pub 3/2009. PMID: 19263231.
18. Fowler N, Younes A. There will be blood: targeting tumor vasculature. Blood 113(10):2121-2122, 3/2009. PMID: 19264922.
19. Fowler N, Asatiani E, Cheson B. Needle tract seeding after bone marrow biopsy in non-Hodgkin lymphoma. Leuk Lymphoma 49(1):156-8, 1/2008. PMID: 18203026.
20. Fowler N, Spell D. Case report. Parotid gland metastasis as the initial manifestation of a non-small cell lung cancer. Southern Medical J. Vol 95:S:25, 2002.

Abstracts

1. Hong DS, Younes A, Fayad LE, Fowler NH, Hagemeister FB, Mistry R, Nemunaitis JJ, Borad MJ, Bryce AH, Yamashita M, Hughes SG, Kwoh TJ, MacLeod R, Norris D, Baldwin R, Hung G, Monia B, Kurzrock R. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. J Clin Oncol ASCO Annual Meeting(8523), 6/2013.
2. Wagner-Johnston N, De Vos S, Leonard J, Porter Sharman J, Schreeder MT, Boccia RV, Barrientos JC, Coutre SE, Flinn I, Boyd TE, Holes L, Johnson DM, Kim Y, Dansey RD, Godfrey WR, Fowler NH. Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL). J Clin Oncol ASCO Annual Meeting(8501), 6/2013.
3. Leonard J, Wagner-Johnston ND, Coutre SE, Flinn I, Schreeder MT, Fowler NH, Sharman JP, Boccia RV, Barrientos JC, Rai KR, Boyd TE, Furman RR, Holes L, Johnson DM, Kim Y, Dansey RD, Godfrey WR, De Vos S. Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study. J Clin Oncol ASCO Annual Meeting(8500), 6/2013.
4. Barrientos JC, Furman RR, Leonard J, Flinn I, Roop Rai K, De Vos S, Schreeder MT, Wagner-Johnston ND, Porter Sharman J, Boyd TE, Fowler NH, Holes L, Johnson DM, Li D, Dansey RD, Jahn TM, Coutre SE. Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. J Clin Oncol ASCO Annual Meeting(7017), 6/2013.
5. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, Baladandayuthapani V, Luong A, Vega F, Fowler N, Dong C, Davis RE, Neelapu SS. Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment. J Immunol, 5/2013. PMID: 23686488.
6. Fowler N, Oki Y. Developing novel strategies to target B-cell malignancies. Am Soc Clin Oncol:366-72, 5/2013. PMID: 23714549.
7. Rawal S, Fowler N, Zhang M, Wang Z, Muzzafar T, Harun N, Baladadayuthapani V, Sharma R, Delgado D, Wallace M, Heise C, Lacerte L, Samaniego F, Davis E, and Neelapu S. Activation of T and NK cells following lenalidomide therapy in patients with follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21) (#2766), 11/2012.
8. Fowler N, de Vos S, Schreeder M, Leonard J, Flinn I, Coutre S, Wagner-Johnston N, Sharman J, Boccia R, Barrientos J, Boyd T, Holes L, Lannutti B, Johnson D, Jahn T, Miller L, and Godfrey W. Combinations of the phosphatidylinositol 3-kinase-delta (PI3Ko) inhibitor Gs-1101 (Cal-101) with rituximab and/or bendamustine are tolerable and highly active in previously treated, indolent non-Hodgkin lymphoma: Results from a phase I study. Blood (ASH Annual Meeting Abstracts) 120(21) (#3645), 11/2012.
9. Coutre S, Leonard J, Furman R, Barrientos J, de Vos S, Flinn I, Schreeder M, Wagner-Johnston N, Sharman J, boyd T, Fowler N, Holes L, Lannutti B, Johson D, Miller L, and Jahn T. Combinations of the slective phosphatidylinositol 3-kinase-delta (PI3Kdelta) inhibitor GS-1101 (Cal-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): Results from a phase I study. Blood (ASH Annual Meeting Abstracts) 120(21) (#191), 11/2012.
10. Fowler N, Neelapu S, Hagemeister F, McLaughlin P, Kwak L, Roamguera J, Fnaale M, Fayad L, Orlowski R, Wang M, Turturro F, Oki Y, Lacerte L, and Samaniego F. Lenalidomide and rituximab for untreated indolent lymphoma: Final results of a phase II study. Blood (ASH Annual Meeting Abstracts) 120(21) (#901), 11/2012.
11. Westin J, Chu F, Fayad L, Kwak L, Fowler N, Romaguera J, Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, and Neelapu S. Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21) (#793), 11/2012.
12. Fanale M, Lai C, Rimes S, Ramirez M, Hagemeister F, Fowler N, Younes A, Fayad L, Rodriguez MA, Turturro F, Samaniego F, Romaguera J, Levin V, Horowitz S, Woolery J, and Milbourne A. Positive maternal-fetal outcomes with treatment of lymphoma during pregnancy: UT MD Anderson Cancer Center prospective experience. Blood (ASH Annual Meeting Abstracts) 120(21) (#3670), 11/2012.
13. Oki Y, Westin J, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak L, Romaguera J, Fanale M, Younes A, Rodrigues MA, Orlowski R, Wang M, Ouzounian S, Samaniego F, and Fayad L. R-HCVAD alternating with R-methotrexate cytrabine in younger patients (pts) with IH and high-risk age adjusted-IPI DLBCL. Blood (ASH Annual Meeting Abstracts) 120(21) (#3707), 11/2012.
14. Oki Y, Chuang H, Chasen B, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister FB, Rodriguez A, Neelapu S, Samaniego F, Kwak L, and Younes A. The prognostic value of interim PET scan in patients with classical Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21) (#1529), 11/2012.
15. Nelson K, Samaniego F, Hagemeister F, Lacerte L, Kwak L Neelapu S, Fayad L, LeBlanc D, and Fowler N. Dermatologic side effects of lenalidomide and rituximab in indolent lymphoma. 2012 Pan Pacific Lymphoma Conference, http://www.unmc.edu/cce/panpacific/index.cfm?L1_ID=21&CONREF=21, 7/2012.
16. Gardner K, Dabaja B, Reed V, Kim M, Gambos D, Sorenson E, and Fowler N. Priamry intraocular diffuse large B-cell lymphoma: Outcomes following combined modality treatment. 2012 Pan Pacific Lymphoma Conference, http://www.unmc.edu/cce/panpacific/index.cfm?L1_ID=21&CONREF=21, 7/2012.
17. Wang M, Fowler N, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M, Younes A, Zhang L, Sun L, Badillo M, Bejarano M, Champlin R, Kwak L, Feng L, Byrne C, Bell N, Zeldis J, Romaguera J, Fayad L. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in a cohort of patients with DLBCL and grade 3 follicular lymphoma: a completed phase II clinical trial. 16th Congress of the European Hematology Association (EHA) (#237), 2012.
18. de Vos S, Schreeder M, Flinn I, Coutre S, Leonard J, Wagner-Johnston N, Fowler N, Boccia R, Barrientos J, Boyd T, Sharman J, Holes L, Lannutti B, Johnson D, Jahn T, and Miller L. A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3Ko) inhibitor, Cal-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin's lymphoma (iNHL). Blood (ASH Annual Meeting Abstracts) 118(21) (#2699), 11/2011.
19. Sharman J, de Vos S, Leonard J, Furman R, Coutre S, Flinn I, Schreeda M, Barrientos J, Wagnor-Johnston N, Boyd T, Fowler N, Holes L, Lannutti B, Johnson D, Jahn T, and Langdon M. A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3Ko) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 118(21) (#1787), 11/2011.
20. Vadhan-Raj S, Spasojevic I, Zhou X, Romaguera J, Fanale M, Fayad L, Fowler N, Huen A, Hagemeister F, Rodriguez M, Neelapu S, Samaniego F, Younes A, and Kwak L. Effects of aprepitant on drug metabolism in lymphoma patients receiving multi-day chemotherapy regimen of cyclophosphamide, doxorubicon, vincristine, prednisone, + rituxan (R/CHOP): Randomized, cross-over study. Blood (ASH Annual Meeting Abstracts) 118(21) (#1613), 11/2011.
21. Khouri I, Saliba R, Valverde R, Samuels B, Korblin M, Alousi A, Anderlini P, Bashir Q, de Lima M, Hosing C, Kebriaei P, Nieto Y, Popat U, Qazilbash M, Neelapu S, Fowler N, Samaniego F, Wang L, Champlin R, and Macainlac H. Nonmyeloablative allogenic stem cell transplantation with/without 90yttrium ibritumomab tiexetan (90YIT) is curative for relapsed follicular lymphoma: Median 9 year follow-up results. Blood (ASH Annual Meeting Abstracts) 118(21) (#662), 11/2011.
22. Fowler N, Neelapu S, Fanale M, Rodriguez M, Pro B, Hagemeister F, Younes A, Shah J, Kwak L, Rodriguez D, and McLaughlin P. Phase II study with R-FND followed by 90-Y Ibritumomab tiuxetan radioimmuntherapy and rituximab maintenance for untreated high-risk follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 118(21) (#99), 11/2011.
23. Fowler N, Munteanu M, Davis G, Brown P, Czuczman M. Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma. Blood (ASH Annual Meeting Abstracts) 118(21), 11/2011.
24. Fowler N, Kahanic S, Ferero A, Murteanu M, Davis G, Brown P, Van Den Neste E, Offner F, Bron D, and Czuczman M. Results of a phase II study with bendamustine and ofatumumab in untreated indolents B-cell non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 118(21) (#778), 11/2011.
25. Fowler N, Hagemeister F, McLaughlin P, Kwak L, Romaguera J, Fanale M, Neelapu S, Fayad L, Orlowski R, Wang W, Pro B, Lacerte L, Samaniego f. High Response Rates with Lenalidomide Plus Rituximab for Untreated Indolent B cell non-Hodgkins Lymphom. Ann Oncol 22(Suppl 4), 6/2011.
26. Fowler N, Mclaughlin P, Fisch M, Dakhil S, Bury M, Fayad L, Shah J, Neelapu S, Romaguera J, Rodriguez D, Ayala A, Kwak L. Rituximab plus sargramostim for the treatment of newly diagnosed follicular lymphoma: Final Results of a Phase II study. Ann Oncol 22(Suppl 4), 6/2011.
27. R. Advani, J. P. Sharman, S. M. Smith, D. A. Pollyea, T. E. Boyd, B. W. Grant, K. S. Kolibaba, J. J. Buggy, A. Hamdy, N. H. Fowler. Btk inhibitor PCI-32765 monotherapy induces objective responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase 1 study. Journal of Clinical Oncology 29(15) (#54096), 5/2011.
28. Okoroji G, Silva L, Saliba R, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, and Khouri I. Outcome in follicular lymphoma (FL) patients (pts) relapsing after autologous stem cell transplantation (ASCT): Allografting vs conventional therapy. Blood (ASH Annual Meeting Abstracts) 116(21) (#3510), 11/2010.
29. Padmanabhan S, Shea T, Vose J, Reeder C, Berdeja J, McDonagh K, Goy A, Kelly K, Zhou X, Liu H, Fingert H, and Fowler N. Phase I study of an investigational aurora A kinase inhibitor MLN8237 in patients with advanced hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 116(21) (#2799), 11/2010.
30. Fowler N, Sharman J, Smith S, Boyd T, Grant B, Kolibaba K, Furman R, Buggy J, Loury D, Hamdy A, and Advani R. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: Results from a phase I study. Blood (ASH Annual Meeting Abstracts) 116(21) (#964), 11/2010.
31. Burger J, O'Brien S, Fowler N, Advani R, Sharman J, Furman R, Izumi R, Buggy J, Loury D, Hamdy A, Byrd J, and Blum K. Thr Bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demostrates promising clinical activity in chronic lymphomcytic leukemia (CLL) and small lymphocytic lymphoma (SLL): An update on ongoing phase I studies. Blood (ASH Annual Meeting Abstracts) 116(21) (#57), 11/2010.
32. Fowler N, Sharman JS, Smith SS, Pollyea DP, Boyd TB, Grant BG, Kolibaba KK, Buggy JB, Hamdy AH, Advani, RA. A Phase I Trial of Btk inhibitor PCI-32765 in patients with relapsed non-Hodgkin's lymphoma: Evidence of antitumor activity. Haematologica 95(371(Suppl 2)) (#0893), 6/2010.
33. Fowler NH, McLaughlin P, Hagemeister FB, Kwak LW, Fanale M, Neelapu SS, Fayad LE, Orlowski RZ, Wang M, Samaniego F. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. ASCO Meeting Abstracts 28(15s (Suppl)) (#8036), 5/2010.
34. Perini GF, Romaguera JE, Rodriguez MA, Pro B, Younes A, Fowler NH, Hagemeister F, Samaniego F, Kwak LW, Fayad L. Diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) involvement, clinica presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at M.D. Anderson Cancer Center. ASCO Meeting Abstracts 28(15s (Suppl)) (#8072), 5/2010.
35. Advani R, Sharman JP, Smith SM, Pollyea DA, Boyd TE, Grant BW, Kolibaba KS, Buggy JJ, Hamdy A, Fowler NH. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. ASCO Meeting Abstracts 28(15s (Suppl)) (#8012), 5/2010.
36. Fowler N, Khan S, and Gilliam M. Non-Hodgkin's lymphoma and hepatitis c: prevalence of co-infection and outcomes following anti-viral therapy: a review of the literature. 2009 Pan Pacific Lymphoma Conference, 8/2009.
37. Cataldo V, Thompson M, Toth B, Sanjoro P, Bekele N, Jimenez C, Murphy W, Huen A, Arbuckle R, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, and Hagemeister F. Bone loss in patients with previously untreated lymphoma: The effect of periodontal disease on the use of zoledronic acid. Blood (ASH Annual Meeting Abstracts) 112:5297, 11/2008.
38. McLaughlin P, Neelapu S, Fanale M, Rodriguez M, Ayala A, Pro B, Hagemeister F, Younes A, Neel S, Fowler N, Hess M, and Kwak L. R-FND followed by radioimmunotherapy for high-risk follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 112:3056, 11/2008.
39. S.A. Siddique, N. Fowler, E. Asatiani, B. Mavromatis, P. Cohen, C.M. Kessler and B.D. Cheson. Infectious complications associated with alemtuzumab treatment. ASCO Meeting Abstracts 25(18S) (#13504), 6/2007.
40. Westin J, Chu F, Fayad L, Kwak L, Fowler N, Romaguera J, Hagemeister F, Allen R, Feng L, Baladandayuthapani V, Yehudar R, Davis E, Neelapu S. Phase II safety and efficacy study of pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma. Annals of Oncology. Submitted.
41. DeVos S, Wilson W, Gerecitano J, Goy A, Kenkre V, Barr P, Blum K, Shustov A, Advani R, Fowler N, Vose J, Lih C, Williams M, Schmitz R, Yang Y, Pittaluga S, Wright, G, Kunkel L, McGreivy J, Beaurpe D, Balasubramanian S, Cheng M, Moussa D, Chang L, Buggy J, Staudt L. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B-cell-like (ABC) subtype of relapsed/refractory (R/R) DLBCL: Interim. Haematologica. Submitted.
42. Coutre S, Leonard J, Furman R, Flinn I, de Vos S, Rai K, Schreeder M, Wagner-Johnston, Sharman J, Boyd T, Fowler N, Kim Y, Holes L, Johnson D, Dansey R, Jahn T, Barrientos J. Update on a phase I study of the selective P13K-delta inhibitor, idelaslisib (GS-1101) in combination with ofatumumab in patients with relapsed or refractory chronic leukemia. Haematologica. Submitted.

Book Chapters

1. Fowler N, McLaughlin P. Non-Hodgkin's Lymphoma. In: Advances in Malignant Hematology. Ed(s) Saba, HI and Mufti, GJ. Wiley-Blackwell: Oxford, UK, 2011.
2. McLaughlin P, Fowler N, Liu N, Medeiros J. The Indolent Lymphomas. In: The MD Anderson Manual of Medical Oncology, 2nd Edition. McGraw-Hill, 2010.
3. Fowler N, Horowitz S, McLaughlin P. Therapy of B-cell lymphoproliferative disorders. In: Experimental and Clinical Hematopathology. Ed(s) D Jones. Springer/Humana, 2010.

Grant & Contract Support

Title: Developing NK-Cell Therapies to Enhance the Treatment of non-Hodgkin Lymphoma
Funding Source: SPORE
Role: Principal Investigator
Duration: 9/1/2010 - 7/31/2011

Last updated: 10/17/2013